Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone781-875-3605
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable
Microbot Medical (NASDAQ:MBOT) Frequently Asked Questions
What is Microbot Medical's stock symbol?
Microbot Medical trades on the NASDAQ under the ticker symbol "MBOT."
When did Microbot Medical's stock split? How did Microbot Medical's stock split work?
Shares of Microbot Medical reverse split before market open on Monday, May 9th 2016. The 1-12 reverse split was announced on Friday, May 6th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 6th 2016. An investor that had 100 shares of Microbot Medical stock prior to the reverse split would have 8 shares after the split.
How were Microbot Medical's earnings last quarter?
Microbot Medical Inc (NASDAQ:MBOT) released its earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.60) by $0.02. View Microbot Medical's Earnings History.
When is Microbot Medical's next earnings date?
What price target have analysts set for MBOT?
1 equities research analysts have issued 12 month price objectives for Microbot Medical's shares. Their forecasts range from $1.75 to $1.75. On average, they expect Microbot Medical's stock price to reach $1.75 in the next year. This suggests that the stock has a possible downside of 63.4%. View Analyst Price Targets for Microbot Medical.
What is the consensus analysts' recommendation for Microbot Medical?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Microbot Medical in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Microbot Medical.
Has Microbot Medical been receiving favorable news coverage?
News coverage about MBOT stock has trended positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Microbot Medical earned a news sentiment score of 2.6 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Microbot Medical.
Are investors shorting Microbot Medical?
Microbot Medical saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 76,500 shares, an increase of 6.0% from the April 15th total of 72,200 shares. Based on an average daily volume of 96,400 shares, the days-to-cover ratio is presently 0.8 days. Currently, 2.2% of the shares of the company are short sold. View Microbot Medical's Current Options Chain.
Who are some of Microbot Medical's key competitors?
Some companies that are related to Microbot Medical include Idera Pharmaceuticals (IDRA), Pluristem Therapeutics (PSTI), Brainstorm Cell Therapeutics (BCLI), Fennec Pharmaceuticals (FENC), Genocea Biosciences (GNCA), Applied Genetic Technologies (AGTC), Outlook Therapeutics (OTLK), Organovo (ONVO), Curis (CRIS), Entera Bio (ENTX), Pharmacyte Biotech (PMCB), Cidara Therapeutics (CDTX), BIONDVAX PHARMA/S (BVXV), Titan Pharmaceuticals (TTNP) and Vical (VICL).
What other stocks do shareholders of Microbot Medical own?
Who are Microbot Medical's key executives?
Microbot Medical's management team includes the folowing people:
- Mr. Harel Gadot, Co-Founder, Pres, CEO & Chairman (Age 46)
- Mr. David Ben Naim CPA, M.B.A., Chief Financial Officer (Age 50)
- Dr. Simon Sharon, CTO & Chairman of Scientific Advisory Board
- Prof. Moshe Shoham, Co-Founder, Scientific Director & Member of Scientific Advisory Board (Age 67)
- Dr. Eric C. Leuthardt, Scientific Director & Member of Scientific Advisory Board
How do I buy shares of Microbot Medical?
Shares of MBOT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Microbot Medical's stock price today?
One share of MBOT stock can currently be purchased for approximately $4.78.
How big of a company is Microbot Medical?
Microbot Medical has a market capitalization of $20.59 million. The biotechnology company earns $-7,240,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Microbot Medical employs 9 workers across the globe.View Additional Information About Microbot Medical.
What is Microbot Medical's official website?
How can I contact Microbot Medical?
Microbot Medical's mailing address is 25 RECREATION PARK DRIVE UNIT 108, HINGHAM MA, 02043. The biotechnology company can be reached via phone at 781-875-3605 or via email at [email protected]
MarketBeat Community Rating for Microbot Medical (NASDAQ MBOT)
MarketBeat's community ratings are surveys of what our community members think about Microbot Medical and other stocks. Vote "Outperform" if you believe MBOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
